

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### P<sub>1</sub>-Purinergeric Receptor-Mediated Modulation of TSH Actions on FRTL-5 Thyroid Cells: Possible Switching From cAMP Pathway to Inositol Phosphate-Ca System

Y. Kondo<sup>a</sup>; K. Sho<sup>a</sup>; M. A. Majid<sup>a</sup>; F. Okajima<sup>a</sup>

<sup>a</sup> Department of Physical Biochemistry, Institute of Endocrinology, Gunma University, Maebashi, Japan

**To cite this Article** Kondo, Y. , Sho, K. , Majid, M. A. and Okajima, F.(1991) 'P<sub>1</sub>-Purinergeric Receptor-Mediated Modulation of TSH Actions on FRTL-5 Thyroid Cells: Possible Switching From cAMP Pathway to Inositol Phosphate-Ca System', *Nucleosides, Nucleotides and Nucleic Acids*, 10: 5, 1217 – 1218

**To link to this Article:** DOI: 10.1080/07328319108047282

**URL:** <http://dx.doi.org/10.1080/07328319108047282>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

P<sub>1</sub>-PURINERGIC RECEPTOR-MEDIATED MODULATION OF TSH ACTIONS  
ON FRTL-5 THYROID CELLS: POSSIBLE SWITCHING FROM CAMP  
PATHWAY TO INOSITOL PHOSPHATE-CA SYSTEM.

Y. Kondo\*, K. Sho, M. A. Majid and F. Okajima  
Department of Physical Biochemistry, Institute of Endocrinology,  
Gunma University, Maebashi 371, Japan.

**Abstract** In thyroid cells, a P<sub>1</sub>-agonist, via G<sub>i</sub> like protein, enhanced a TSH-induced I<sup>-</sup>-efflux by intensifying a TSH-dependent inositol polyphosphate production followed by a Ca<sup>2+</sup> mobilization, but diminished a TSH-dependent DNA synthesis by attenuating a TSH-dependent cAMP accumulation.

In FRTL-5 cells, a cell line derived from normal rat thyroid, TSH stimulates <sup>131</sup>I-efflux as a process of thyroid hormone synthesis, which is mediated by intracellular Ca<sup>2+</sup> mobilization <sup>1)</sup>, and increase <sup>3</sup>H-thymidine incorporation into DNA as a process of growth promotion, which involves a stimulation of cAMP production <sup>2)</sup>. Recently, we found that P<sub>1</sub>-purinergic receptor agonists such as adenosine phenylisopropyladenosine (PIA) prevented an forskolin-dependent adenylate cyclase activation<sup>3)</sup>, but enhanced an  $\alpha_1$ -adrenergic agonist-induced Ca<sup>2+</sup> mobilization<sup>4)</sup>. Both PIA actions were sensitive to an islet-activating protein (IAP), pertussis toxin treatment of the cells. This led us to examine the modulation of the TSH signal transduction by P<sub>1</sub>-purinergic agonists.

One tenth  $\mu$ M PIA remarkably enhanced TSH-dependent <sup>131</sup>iodide efflux for 1 min from previously labeled FRTL-5 cells, whereas the P<sub>1</sub>-agonist significantly reduced <sup>3</sup>H-thymidine incorporation into DNA for 24 hr. Both PIA effect completely disappeared after the treatment of the cells with IAP. To identify the action site of PIA in the signal transduction pathways for TSH, PIA modulations of the cAMP and Ca responses of to TSH were investigated. In the presence of 0.1  $\mu$ M PIA, <sup>3</sup>H-inositol polyphosphate production induced by 10<sup>-8</sup>M TSH and the intracellular Ca<sup>2+</sup> increase

by graded doses of TSH were remarkably enhanced and the dose-response curve of Ca response shifted 1 to 2 orders to the left. The minimum effective dose of TSH was  $10^{-10}$ M. Prior treatment of the cells with 50 ng/ml IAP abolished this PIA effect, indicating the participation of  $G_i$  or an IAP-sensitive G-protein(s). The  $Ca^{2+}$  response to TSH increased with PIA doses from  $10^{-11}$  to  $10^{-5}$ M, and its  $EC_{50}$  was around  $10^{-8}$ M. On the contrary, PIA dose-dependently inhibited the TSH-induced cAMP accumulation in FRTL-5 cells.  $EC_{50}$  of PIA for the cAMP response was about one order lower than that for the Ca response. When 0.5 U/ml of adenosine deaminase was added to the reaction medium, as for at least one TSH action, the induction of cAMP accumulation was significantly enhanced. In IAP-treated cells, the level of TSH-induced cAMP accumulation reached that obtained by deaminase treatment of control cells, but no further increase was observed even

when adenosine deaminase was added. These deaminase effects proved that endogenous as well as exogenous adenosine acts on FRTL-5 cells as an autocrine agent. When we consider a possible neuronal supply of




Fig. 1 Adenosine modulation of TSH actions pathway (Fig. 1).

adenosine in addition to the autocrine one, the present findings suggest that, in the thyroid, under certain conditions, an adenosine signal mediated by  $G_i$ -like protein switches a TSH signal from the cAMP pathway to the  $Ca^{2+}$

#### REFERENCES

- 1) Weiss, S. J.; Philp, N. J.; Grollman, E. F. *Endocrinology* 1984 114 1108-1113
- 2) Ealey, P. A.; Ahene, C. A.; Emmerson, J. M.; Marshall, N. J. *J. Endocrinol.* 1987 114 199-205
- 3) Okajima, F.; Sato, K.; Nazarea, M.; Sho, K.; Kondo, Y. *J. Biol. Chem.* 1989 264 13029-13037
- 4) Okajima, F.; Sato, K.; Sho, K.; Kondo, Y. *FEBS Lett.* 1989 248 145-149